Ruiyi Biotechnology (Realbio Technology)
Ruiyi Biotechnology is a national high-tech enterprise
About Ruiyi Biotechnology (Realbio Technology)
RealBio is a cutting-edge startup specializing in early and accurate tumor detection, with a particular focus on colorectal cancer. The company has developed a patented test called COLOWELL, which uses advanced technology to predict the risk of colorectal cancer. This test works by analyzing the methylation levels of two specific genes, SFRP2 and SDC2, found in cells shed in stool samples. By leveraging a large sample data analysis model, COLOWELL can provide highly accurate predictions, making it a valuable tool in early cancer detection.
RealBio operates in the healthcare and biotechnology market, serving a range of clients including hospitals, clinics, and diagnostic laboratories. These clients are looking for reliable and non-invasive methods to detect cancer early, which can significantly improve patient outcomes and reduce treatment costs.
The company's business model is based on selling its COLOWELL test kits to healthcare providers. These providers then use the kits to test patients and identify those at risk of colorectal cancer. RealBio generates revenue through the sale of these kits and potentially through partnerships or licensing agreements with larger medical and diagnostic companies.
RealBio's participation in events like the AACC Annual Scientific Meeting and Clinical Lab Expo highlights its commitment to staying at the forefront of clinical diagnostics and medical equipment innovation. This exposure helps the company build credibility and expand its market reach.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 17.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Hospital, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2020 | $0 | — | Undisclosed | — |
| SERIES A✓Equity / VC | Apr 2019 | $15M | $60M | Luxin Venture Capital · Marathon Venture Partners · Wuxi Capital | — |
Growth signals
Latest recorded traffic for Ruiyi Biotechnology (Realbio Technology) is 1.1K monthly website visits, down 90.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ruiyi Biotechnology (Realbio Technology) in its local ecosystem
The Ruiyi Biotechnology (Realbio Technology) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- LCLuxin Venture Capital
Wuxi Capital- MPMarathon Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ruiyi Biotechnology (Realbio Technology) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ruiyi Biotechnology (Realbio Technology)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








